EUVIMEDEUVIMED entdecken
Crossref

Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy

Hannes Erdmann, Florentine Scharf, Stefanie Gehling, Anna Benet-Pagès, Sibylle Jakubiczka, Kerstin Becker, Maria Seipelt, Felix Kleefeld, Karl Christian Knop, Eva-Christina Prott, Miriam Hiebeler, Federica Montagnese iD und 10 weitere

Brain · 2023

DOI: 10.1093/brain/awac336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Hannes Erdmann und 21 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetics Center (MGZ), 80335 Munich, Germany. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic diagnosis of facioscapulohumeral muscular dystrophy (FSHD) remains a challenge in clinical practice as it cannot be detected by standard sequencing methods despite being the third most common muscular dystrophy. The conventional diagnostic strategy addresses the known genetic parameters of FSHD: the required presence of a permissive haplotype, a size reduction of the D4Z4 repeat of chromosome 4q35 (defining FSHD1) or a pathogenic variant in an epigenetic suppressor gene (consistent with FSHD2). Incomplete penetrance and epistatic effects of the underlying genetic parameters as well as epigenetic parameters (D4Z4 methylation) pose challenges to diagnostic accuracy and hinder prediction of clinical severity. In order to circumvent the known limitations of conventional diagnostics and to complement genetic parameters with epigenetic ones, we developed and validated a multistage diagnostic workflow that consists of a haplotype analysis and a high-throughput methylation profile analysis (FSHD-MPA). FSHD-MPA determines the average global methylation level of the D4Z4 repeat array as well as the regional methylation of the most distal repeat unit by combining bisulphite conversion with next-generation sequencing and a bioinformatics pipeline and uses these as diagnostic parameters. We applied the diagnostic workflow to a cohort of 148 patients and compared the epigenetic parameters based on FSHD-MPA to genetic parameters of conventional genetic testing. In addition, we studied the correlation of repeat length and methylation level within the most distal repeat unit with age-corrected clinical severity and age at disease onset in FSHD patients. The results of our study show that FSHD-MPA is a powerful tool to accurately determine the epigenetic parameters of FSHD, allowing discrimination between FSHD patients and healthy individuals, while simultaneously distinguishing FSHD1 and FSHD2. The strong correlation between methylation level and clinical severity indicates that the methylation level determined by FSHD-MPA accounts for differences in disease severity among individuals with similar genetic parameters. Thus, our findings further confirm that epigenetic parameters rather than genetic parameters represent FSHD disease status and may serve as a valuable biomarker for disease status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralHumansDNA MethylationHaplotypesChromosomes, Human, Pair 4

Stichwörter der Autor:innen

FSHDbisulphite sequencingepigeneticsmethylation

Autor:innen und Institutionen

  • Medical Genetics Center (MGZ), 80335 Munich, Germany.
  • Friedrich-Baur-Institute, Department of Neurology, Klinikum der Universität, Ludwig-Maximilians-Universität, 80336 Munich, Germany.
  • Institute of Neurogenomics, Helmholtz Center Munich, 85764 Neuherberg, Germany.
  • Institute of Human Genetics, Universitätsklinikum Magdeburg, Otto-von-Guericke Universität, 39120 Magdeburg, Germany.
  • Department of Neurology, Universitätsklinikum Marburg, Philipps-University Marburg, 35043 Marburg, Germany.
  • Department of Neurology and Experimental Neurology, Charité Berlin, 10117 Berlin, Germany.

ORCID-Profile: Federica Montagnese, Angela Abicht

Zitieren

APA

Erdmann, H., Scharf, F., Gehling, S., Benet-Pagès, A., Jakubiczka, S., Becker, K., Seipelt, M., Kleefeld, F., Knop, K. C., Prott, E. C., Hiebeler, M., Montagnese, F., Gläser, D., Vorgerd, M., Hagenacker, T., Walter, M. C., Reilich, P., Neuhann, T., Zenker, M., …, & Abicht, A. (2023). Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy. Brain. https://doi.org/10.1093/brain/awac336

Vancouver

Erdmann H, Scharf F, Gehling S, Benet-Pagès A, Jakubiczka S, Becker K, et al. Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy. Brain. 2023. doi:10.1093/brain/awac336

BibTeX
@article{Erdmann2023,
  author = {Erdmann, Hannes and Scharf, Florentine and Gehling, Stefanie and Benet-Pagès, Anna and Jakubiczka, Sibylle and Becker, Kerstin and Seipelt, Maria and Kleefeld, Felix and Knop, Karl Christian and Prott, Eva-Christina and Hiebeler, Miriam and Montagnese, Federica and Gläser, Dieter and Vorgerd, Matthias and Hagenacker, Tim and Walter, Maggie C and Reilich, Peter and Neuhann, Teresa and Zenker, Martin and Holinski-Feder, Elke and Schoser, Benedikt and Abicht, Angela},
  title = {Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy},
  journal = {Brain},
  year = {2023},
  doi = {10.1093/brain/awac336}
}
Kostenlos starten →